News Related to Motion Sickness

Related coverage linked through entity extraction aliases.

FDA Approves Vanda's Bysanti for Schizophrenia and Bipolar I Disorder

Feb 20, 2026

Vanda Pharmaceuticals received FDA approval for Bysanti (milsaperidone), an atypical antipsychotic for schizophrenia and manic or mixed episodes in bipolar I disorder. The drug will be available by the third quarter of 2026.

FDA Approves Tradipitant for Motion Sickness, First New Treatment in Over 40 Years

Nov 28, 2025

The FDA approved tradipitant (Nereus), an oral NK-1 receptor antagonist, for prevention of motion-induced vomiting on December 30, 2025. The approval marks the first new pharmacologic treatment for motion sickness in over four decades.